Mar 6, 2026 08:01AM
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM
Mar 6, 2026 08:00AM
Feb 18, 2026 08:15AM
Feb 18, 2026 08:15AM
Feb 3, 2026 08:00AM Allarity opens Phase 2 trial combining stenoparib with temozolomide
Feb 3, 2026 08:00AM
Dec 31, 2025 08:00AM
Nov 14, 2025 09:00AM
Sep 22, 2025 08:01AM
Sep 22, 2025 08:00AM
Aug 26, 2025 08:00AM
Aug 26, 2025 08:00AM Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
Jun 2, 2025 08:00AM
Jun 2, 2025 08:00AM
May 9, 2025 04:05PM
Apr 25, 2025 08:01AM
Apr 25, 2025 08:00AM
Mar 31, 2025 04:05PM
Mar 13, 2025 08:33AM Allarity Therapeutics (ALLR) Announces Final Settlement with the U.S. Securities and Exchange Commission
Mar 13, 2025 08:30AM
Mar 6, 2025 08:00AM
Feb 24, 2025 08:00AM
Feb 6, 2025 08:01AM
Feb 6, 2025 08:00AM
Jan 30, 2025 08:06AM
Jan 30, 2025 08:00AM Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Nov 18, 2024 08:03AM
Nov 18, 2024 08:00AM
Nov 14, 2024 08:00AM
Oct 18, 2024 12:47PM
Jul 22, 2024 06:32AM
Jul 22, 2024 06:30AM
Jun 25, 2024 08:00AM Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
May 14, 2024 04:01PM
May 2, 2024 08:03AM
May 2, 2024 08:00AM
Dec 5, 2023 07:31AM
Dec 5, 2023 07:30AM
Jul 5, 2023 09:46AM
Jul 5, 2023 09:45AM Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Apr 27, 2023 09:02AM
Apr 27, 2023 09:00AM
Oct 11, 2022 04:05PM
Oct 11, 2022 04:05PM
Aug 2, 2022 06:03AM
Aug 2, 2022 06:00AM
Aug 2, 2022 06:00AM Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
May 16, 2022 07:40PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All